Last reviewed · How we verify
NCT06161142: COHIR
Characteristics of Hypophosphatasia in Adult Patients in Rheumatology
trial testing Second alkaline phosphatase measurement in Hypophosphatasia in 60 participants. Status unknown.
1 December 2024
Quick facts
| Lead sponsor | University of Bonn |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 28 February 2023 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Second alkaline phosphatase measurement
- Extended laboratory diagnostics
- Symptom and clinical findings checklist for hypophosphatasia
- SF-36
- Short physical performance battery (SPPB) score
- Physical examination
- Recording of vital signs
- Bioelectrical Impedance Analysis
- Genetic testing of the alkaline phosphatase gene
Conditions studied
- Hypophosphatasia — all drugs for Hypophosphatasia →
Sponsor
University of Bonn
Who can join
18 and older, any sex, with Hypophosphatasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With hypophosphatasia still being frequently overlooked and misdiagnosed, the primary aim of this prospective observational study is to determine the prevalence of hypophosphatasia in adult patients in rheumatology, and beyond that to establish an algorithm that promotes early hypophosphatasia detection in clinical practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06161142
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypophosphatasia
Currently open trials in the same condition.
- NCT07390240 — The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia · recruiting
- NCT06079359 — Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP · Phase 3 · active not recruiting
- NCT06079372 — Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa · Phase 3 · active not recruiting
- NCT06079281 — Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Trea · Phase 3 · active not recruiting
- NCT05234567 — A Prospective Sub-Study of the Global Hypophosphatasia Registry · recruiting
Other University of Bonn trials
Trials by the same sponsor.
- NCT06954844 — tVNS and Obesity-related Mechanisms · NA · enrolling by invitation
- NCT06700954 — Effects of a Legume-rich Diet in the Context of the Planetary Health Diet Compared to a Western-oriented Dietary Pattern · NA · not yet recruiting
- NCT06618729 — Effects of Plant-based Meat Alternatives in Comparison to Chicken Meat on Postprandial Metabolism in Healthy Adults · NA · completed
- NCT06495255 — Bioavailability of Human Milk Oligosaccharides in Healthy Adults · NA · recruiting
- NCT06270901 — Acute Effects of Legume-enriched Meals Compared to Western Diet Meals on Postprandial Metabolism in Participants with In · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06161142 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Bonn
- Last refreshed: 7 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06161142.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing